PD-1 inhibitor-associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation—Report of 4 cases

Journal of Cutaneous Pathology

Volumn 44, Issue 10, 2017, Pages 851-856

  Chou, Shaun ^a   Zhao, Cathy ^a,b   Hwang, Shelley Ji Eun ^a,b   Fernandez Penas, Pablo ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

anti CTLA 4; anti PD1; dermatologic toxicities; lichenoid inflammation; pemphigus

Indexed keywords

IPILIMUMAB; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ACANTHOLYSIS; AGED; ANTAGONISTS AND INHIBITORS; CASE REPORT; CHEMICALLY INDUCED; FEMALE; HUMAN; LICHENOID ERUPTION; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN;

ACANTHOLYSIS; AGED; FEMALE; HUMANS; IPILIMUMAB; LICHENOID ERUPTIONS; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN;

EID: 85029681029     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/cup.13013     Document Type: Article

References (27)

1. Rivzi N, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257-265.
2. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956-965.
3. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
4. Hamid O, Robert C, Daud A, et al. Safety and tumour responses with lambrolizumab (anti-PD1) in melanoma. N Engl J Med. 2013;369:134-144.
5. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34.
6. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521-2532.
7. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320-330.
8. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006-2017.
9. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109-1117.
10. Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2013;69:e121-e128.
11. Hwang SJE, Carlos G, Wakade D, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016;74(3):455-461.e1.
12. Chou S, Hwang SJE, Carlos G, Wakade D, Fernandez-Penas P. Histologic assessment of lichenoid dermatitis observed in patients with advanced malignancies on anti-Programmed cell Death-1 (anti-PD1) therapy with or without ipilimumab. Am J Dermatopathol. 2017;39(1):23-27.
13. Wakade DV, Carlos G, Hwang SJE, Chou S, Hui R, Fernandez-Penas P. PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases. Melanoma Res. 2016;26:421-424.
14. Jour G, Glitza SC, Ellis RM, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD1 antibody therapy: a report of on bullous skin eruptions. J Cutan Pathol. 2016;43:688-696.
15. Carlos G, Anforth R, Chou S, Clements A, Fernandez-Penas P. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res. 2015;25(3):265.
16. Hwang SJE, Carlos G, Chou S, Wakade D, Carlino MS, Fernandez-Penas P. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Res. 2016;26(4):413-416.
17. Naidoo J, Schindler K, Querfeld C, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res. 2016;4(5):383-389.
18. Tetzlaff MT, Nagarajan P, Chon S, et al. Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features. Am J Dermatopathol. 2017;39(2):121-129.
19. Schaberg KB, Novoa RA, Wakelee HA, et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD1 therapy. J Cutan Pathol. 2016;43:339-346.
20. Yong AA, Tey HL. Paraneoplastic pemphigus. Australas J Dermatol. 2013;54:241-250.
21. Ohzono A, Sogame R, Li X, et al. Clinical and immunological findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol. 2015;173:1447-1452.
22. Fernandez-Figueras MT, Puig L, Cannata P, et al. Grover disease: a reappraisal of histopathological diagnostic criteria in 120 cases. Am J Dermatopathol. 2010;32(6):541-549.
23. Al-Muriesh M, Abdul-Fattah B, Wang X, Zhao M, Chen S, Huang C. Papular acantholytic dyskeratosis of the anogenital and genitocrural area: case series and review of the literature. J Cutan Pathol. 2016;43:749-758.
24. Sanchez-Carpeintero I, Epana A, Pelacho B, et al. In vivo blockade of pemphigus vulgaris acantholysis by inhibition of intracellular signal transduction cascades. Br J Dermatol. 2004;151:565-570.
25. Lanza A, Cirillo N, Fermiano F, Gombos F. How does acantholysis occur in pemphigus vulgaris. J Cutan Pathol. 2006;33:401-412.
26. Dhitavat J, Fairclough RJ, Hovmanian A, Burge SM. Calcium pumps and keratinocytes: lessons from Darier's disease and Hailey-Hailey disease. Br J Dermatol. 2004;150:821-828.
27. Paslin D. Grover disease may result from the impairment of keratinocytic cholinergic receptors. J Am Acad Dermatol. 2012;66(2):332-333.